



**29<sup>th</sup> Annual Cancer Progress Conference**  
**May 8-9, 2018**  
**Convene at 32 Old Slip, NYC**

**Tuesday, May 8, 2018**

**7:00 – 8:00am**      **Registration and Continental Breakfast**

**8:00 – 8:15am**      **Opening Remarks**

Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health

**8:15 – 9:15am**      **Keynote:**

Laura Esserman, MD, MBA, Director, UCSF Carol Franc Buck Breast Cancer Center; Alfred A. de Lorimier Endowed Chair in General Surgery; Professor of Surgery and Radiology, UCSF

**9:15 – 10:30am**      **Cell Therapies as the New Space Race: Engineering Generation X.0**

Moderator: Mike Rice, MS, MBA, Principal, Defined Health

**Panelists:**

- Renier Brentjens, MD, PhD, Medical Oncologists; Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center
- Nouhad Hussein, Head of Business Development, Regeneron Pharmaceuticals, Inc.
- Stanley Frankel, MD, Corporate Vice President, Global Clinical R&D Hematology/Oncology, Celgene
- Julianne Smith, PhD, Vice President, Translational Sciences, Collectis
- Pascal Touchon, Senior Vice President & Global Head, Cell & Gene therapy, Novartis Oncology

**10:30 – 11:00am**      **Networking Break**

**11:00 – 12:15pm**      **Oncology Diagnostics – Reading the Future**

Moderator: Joel Sandler, PhD, Associate Principal, Defined Health

**Panelists:**

- Sharon Benzeno, PhD, MBA, Senior Vice President, Research and Business Development, Adaptive Biotechnologies
- Ken Bloom, MD, President, Human Longevity
- Lisa H. Butterfield, PhD, Professor of Medicine, Surgery, Immunology and Clinical and Translational Science; Director, Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, UPMC Hillman Cancer Center
- Alessandra Cesano, MD, PhD, Chief Medical Officer, NanoString
- Leora Schiff, MS, MBA, Principal, Altius Strategy Consulting, LLC

**12:15 – 1:30pm**      **Networking Luncheon**





**1:30 – 2:45pm**

**Progress in Intractable Cancers- Part I – Heme Malignancies**

Moderator: Mike Rice, MS, MBA, Principal, Defined Health

Panelists:

- Kenneth Anderson, MD, Kraft Family Professor of Medicine, Harvard Medical School
- Stanley Frankel, MD, Corporate Vice President, Global Clinical R&D Hematology/Oncology, Celgene
- William Matsui, MD, Professor of Oncology, Johns Hopkins

**2:45 – 4:00pm**

**Innovative Trials & Collaborative Initiatives – Role of Patient Advocacy, Foundations & Institutes**

Moderator: Jeremy Goldberg, President, JPG Healthcare LLC

Panelists:

- Lou DeGennaro, PhD, President and Chief Executive Officer, The Leukemia & Lymphoma Society
- Lorraine Egan, President and Chief Executive Officer, Damon Runyon
- Ramy Ibrahim, MD, Vice President, Clinical Research & Development, Parker Institute
- T.J. Sharpe, Patient Writer, Speaker, & Patient Experience Advisor, Starfish Harbor, LLC

**4:00 – 4:15pm**

**Networking Break**

**4:15 – 5:30pm**

**Value & Pricing Redux – Does the Song Remain the Same?**

Moderator: Ed Saltzman, Executive Chairman, Defined Health

Panelists:

- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Daniel Becker, MD, MS, Section Chief, Hematology and Oncology, VA-NYHHS; Assistant Clinical Professor of Medicine, New York University School of Medicine
- Kapil Dhingra, MD, Managing Member, KAPital Consulting
- Roger Longman, Chief Executive Officer, Real Endpoints

**5:30 – 7:30pm**

**Cancer Progress 2018 Reception**

**Wednesday, May 9, 2018**

**7:00 – 8:00am**

**Registration and Continental Breakfast**

**8:00 – 8:15am**

**Opening Remarks: Review of Day 1**

Mike Rice, MS, MBA, Principal, Defined Health





**8:15 – 9:30 am**

**Advances in Intractable Cancers - Part II – Solid Tumors**

Moderator: James Lee, PhD, Associate Principal, Oncology Lead, Defined Health

Panelists:

- Michael Tomblyn, MD, MS, Head of US Development & US Medical Director, Nanobiotix
- David Tuveson, MD, PhD, Professor; Director of the Lustgarten Foundation Pancreatic Research Laboratory at CSHL; Director of Research for the Lustgarten Foundation
- Denise Reinke, MS, NP, MBA, President and Chief Executive Officer, SARC
- Wendy K.D. Selig, Founder and Chief Executive Officer, WSCollaborative, LLC

**9:30 – 10:00am**

**Networking Break**

**10:00 – 11:15am**

**Innate & Adaptive Resistance to IO – Is It the TME's Time to Shine?**

Moderator: Mark Simon, Managing Director, Torreya

Panelists:

- Tom Gajewski, MD, PhD, Professor, Department of Pathology, The Ben May Department for Cancer Research, Department of Medicine- Section of Hematology/Oncology, University of Chicago
- Sumayah Jamal, MD, PhD, President, Co-Founder and Chief Scientific Officer, ENB Therapeutics
- Llew Keltner, MD, PhD, Chief Executive Officer, Epistat
- Timothy Reilly, PhD, DABT, Vice President, Head of Oncology Early Asset Development, Bristol-Myers Squibb
- Dmitriy Zamarin, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center

**11:15 – 12:30**

**Next Wave Antibodies and Biologics: Is IO Poised for a Sea of Change?**

Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health

Panelists:

- Mike Curran, PhD, Assistant Professor, The University of Texas, MD Anderson Cancer Center
- John Haurum, MD, DPhil, Chief Executive Officer, F-Star
- Louis Matis, MD, Chief Development Officer, Pieris Pharmaceuticals
- Carsten Reinhardt, MD, PhD, Chief Medical Officer, Immatics
- Taylor Schreiber, MD, PhD, Chief Scientific Officer, Shattuck Labs, Inc.

**12:30 – 1:45pm**

**Networking Lunch**

**1:45 – 3:00 pm**

**Point-Counterpoint: Cancer Progress, at the Crossroads or at a Tipping Point?**

Moderator: Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health





Panelists:

- Axel Hoos, MD, PhD, Senior Vice President, Therapeutic Area Head R&D, GlaxoSmithKline
- Christoph Lengauer, PhD, Venture Partner, Third Rock Ventures
- Brian Leyland-Jones, MBBS, PhD, Vice President, Avera Cancer Institute Center for Precision Oncology and Department of Molecular and Experimental Medicine, Avera Cancer Institute
- Peter Sandor, MD, MBA, Vice President, Head of Oncology Therapeutic Area Marketing, Astellas Pharma US, Inc.

**3:00 pm**

**Cancer Progress 2018 Conference Concludes**